The community of innovative companies at The Oxford Science Park, one of the UK’s leading parks for science and technology companies, is being enhanced by the addition of MiroBio, a novel therapeutics company based on insights into the regulation of receptor signalling in immune cells. MiroBio, which launched in October last year with a £27m Series A round, is taking laboratory and office space at the Park as it expands its drug discovery work. The company’s 15-strong team, most of whom are scientists, is expected to grow further as the company develops.
MiroBio was spun out in 2019 from the laboratories of Simon Davis, Professor of Molecular Immunology at the MRC Weatherall Institute of Molecular Medicine, and Richard Cornall, Nuffield Professor of Clinical Medicine at the University of Oxford. Initially, the company is focusing on auto-immune disease, and is exploring other disease areas opportunistically. It was previously based at the Oxford BioEscalator, where many life sciences start-ups are based when they first spin out from the University.
Piers Scrimshaw-Wright, CEO of The Oxford Science Park, said, ‘MiroBio is a very welcome addition to our innovation community, and we look forward to seeing the company develop further. As a spin-out of the University and a ‘graduate’ of the BioEscalator now taking space at The Oxford Science Park, it is a fine example of Oxford’s ecosystem flourishing.’
For more information, please contact:
Emma Palmer Foster, Strategic Communications Consultant. T: +44 (0)7880 787185 email@example.com